bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 3 from Molecular Modulation of Estrogen-Induced Apoptosis by Synthetic Progestins in Hormone Replacement Therapy: An Insight into the Women's Health Initiative Study
Authors: Sweeney Elizabeth E. , Fan Ping , Jordan V. Craig
Published: April 2023

Supplementary Figure 3. MCF-7:WS8 cells were treated with Dex (A), MPA (B), or NETA (C), at concentrations ranging from 10-10 M to 10-6 M alone or in combination with 1µM 4-OHT, 1µM ICI 182,780, or 1µM RU486 for seven days, and DNA was quantified.
Supplementary Figures 1-19 from ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis
Authors: Martinengo Cinzia , Poggio Teresa , Menotti Matteo , Scalzo Maria Stella , Mastini Cristina , Ambrogio Chiara , Pellegrino Elisa , Riera Ludovica , Piva Roberto , Ribatti Domenico , Pastorino Fabio , Perri Patrizia , Ponzoni Mirco , Wang Qi , Voena Claudia , Chiarle Roberto
Published: April 2023

Supplementary Figures 1-19. Supplementary Figure 1. Hypoxia pathways are enriched in ALCL. Supplementary Figure 2. Gene expression data on ALCL. Supplementary Figure 3. EML4-ALK NSCLC show enrichment in hypoxia pathway associated genes. Supplementary Figure 4. ALK regulates HIF-1ÃŽÂ± and HIF-2ÃŽÂ± expression in ALK-rearranged ALCL cell lines. Supplementary Figure 5. Oncogenic ALK regulates HIF-1ÃŽÂ± and HIF-2ÃŽÂ± expression levels in ALK-rearranged ALCL cell lines. Supplementary Figure 6. Oncogenic ALK-mediated control of HIF-1ÃŽÂ± and HIF-2ÃŽÂ± expression is not dependent on proteasome-dependent degradation. Supplementary Figure 7. ALK regulates HIF-1ÃŽÂ± and HIF-2ÃŽÂ± through STAT3 and C/EBPÃŽÂ². Supplementary Figure 8. STAT3 and C/EBPÃŽÂ² mediated regulation of HIFs in ALCL. Supplementary Figure 9. Ectopic expression of NPM-ALK in ALK negative ALCL. Supplementary Figure 10. Validation of shRNA against HIF-1ÃŽÂ± and HIF-2ÃŽÂ±. Supplementary Figure 11. HIF-2ÃŽÂ± is essential for the growth of ALK-rearranged ALCL in vivo. Supplementary Figure 12. HIF-1ÃŽÂ± and HIF-2ÃŽÂ± are not required for the growth of ALK-negative T cell lymphoma in vivo. Supplementary Figure 13. ALK regulates VEGFA mRNA expression and production in vitro. Supplementary Figure 14. Anti-angiogenic treatment in ALK negative ALCL. Supplementary Figure 15. Oncogenic ALK regulates HIF-1ÃŽÂ± and HIF-2ÃŽÂ± expression levels in EML4-ALK NSCLC. Supplementary Figure 16. HIF-ÃŽÂ± regulation in NSCLC is specifically dependent on ALK activity. Supplementary Figure 17. Oncogenic ALK activity up-regulates VEGF expression in NSCLC. Supplementary Figure 18. HIF-ÃŽÂ± knock-down does not affect the growth of K-RAS mutated NSCLC. Supplementary Figure 19. HIF-1ÃŽÂ± and HIF-2ÃŽÂ± are essential for metastasis formation in EML4-ALK NSCLC.
Supplemental Figure Legend from Targeted Noninvasive Imaging of EGFR-Expressing Orthotopic Pancreatic Cancer Using Multispectral Optoacoustic Tomography
Authors: Hudson Shanice V. , Huang Justin S. , Yin Wenyuan , Albeituni Sabrin , Rush Jamie , Khanal Anil , Yan Jun , Ceresa Brian P. , Frieboes Hermann B. , McNally Lacey R.
Published: April 2023

Supplemental Figure Legend. Legend for Supplemental Figure S1.
Supplementary Figure Legends from ALK-Dependent Control of Hypoxia-Inducible Factors Mediates Tumor Growth and Metastasis
Authors: Martinengo Cinzia , Poggio Teresa , Menotti Matteo , Scalzo Maria Stella , Mastini Cristina , Ambrogio Chiara , Pellegrino Elisa , Riera Ludovica , Piva Roberto , Ribatti Domenico , Pastorino Fabio , Perri Patrizia , Ponzoni Mirco , Wang Qi , Voena Claudia , Chiarle Roberto
Published: April 2023

Supplementary Figure Legends. File with Supplementary Figure Legends
Supporting information_Figure legends from mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress
Authors: Li Jing , Shin Sejeong , Sun Yang , Yoon Sang-Oh , Li Chenggang , Zhang Erik , Yu Jane , Zhang Jianming , Blenis John
Published: April 2023

This document contains figure legends for the supporting figures
Supplementary Methods from Influence of Drug Formulation on OATP1B-Mediated Transport of Paclitaxel
Authors: Nieuweboer Annemieke J.M. , Hu Shuiying , Gui Chunshan , Hagenbuch Bruno , Ghobadi Moghaddam-Helmantel Inge M. , Gibson Alice A. , de Bruijn Peter , Mathijssen Ron H.J. , Sparreboom Alex
Published: April 2023

PDF file - 58KB
Figure S4. The combination of BSO and rapamycin induces mitochondrial ROS and alters mitochondrial morphology from mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress
Authors: Li Jing , Shin Sejeong , Sun Yang , Yoon Sang-Oh , Li Chenggang , Zhang Erik , Yu Jane , Zhang Jianming , Blenis John
Published: April 2023

mitochondrial ROS levels measurement in Tsc2-/- MEFs and WT MEFs treated with indicated compounds
Supplementary Figure 2 from Influence of Drug Formulation on OATP1B-Mediated Transport of Paclitaxel
Authors: Nieuweboer Annemieke J.M. , Hu Shuiying , Gui Chunshan , Hagenbuch Bruno , Ghobadi Moghaddam-Helmantel Inge M. , Gibson Alice A. , de Bruijn Peter , Mathijssen Ron H.J. , Sparreboom Alex
Published: April 2023

PDF file - 151KB, The uptake of paclitaxel by human OATP1B1, human OATP1B3 in CHO cells (1 microM; 2-min), or mouse OATP1B2 in HEK293 cells (0.1 microM; 15-min) evaluated in the absence (none) or presence of 1 percent (w/v) Cremophor EL (CrEL).
Supplementary Figure 1 from Influence of Drug Formulation on OATP1B-Mediated Transport of Paclitaxel
Authors: Nieuweboer Annemieke J.M. , Hu Shuiying , Gui Chunshan , Hagenbuch Bruno , Ghobadi Moghaddam-Helmantel Inge M. , Gibson Alice A. , de Bruijn Peter , Mathijssen Ron H.J. , Sparreboom Alex
Published: April 2023

PDF file - 636KB, In vitro transport of paclitaxel by OATP1B1 and OATP1B3.
Supplementary Figure 2 from A Hypusine–eIF5A–PEAK1 Switch Regulates the Pathogenesis of Pancreatic Cancer
Authors: Fujimura Ken , Wright Tracy , Strnadel Jan , Kaushal Sharmeela , Metildi Cristina , Lowy Andrew M. , Bouvet Michael , Kelber Jonathan A. , Klemke Richard L.
Published: April 2023

Contains additional data on the growth of PDAC cells with eIF5A knockdown or overexpression.
pplementary Figure 1, Table 1 from Cell Surface Lactate Receptor GPR81 Is Crucial for Cancer Cell Survival
Authors: Roland Christina L. , Arumugam Thiruvengadam , Deng Defeng , Liu Shi He , Philip Bincy , Gomez Sobeyda , Burns William R. , Ramachandran Vijaya , Wang Huamin , Cruz-Monserrate Zobeida , Logsdon Craig D.
Published: April 2023

PDF file - 163K, Supplementary Figure 1: Lentiviral shRNA mediated knockdown or ectopic expression of GPR81. Supplementary Figure 2: Lentiviral shRNA mediated knockdown of GPR81 is associated with reduced levels of MCT1. Supplemental Table 1: Primer sequences for quantitative RT-PCR.
Supplemental Figure Legends from Targeting Cancer Stem–like Cells as an Approach to Defeating Cellular Heterogeneity in Ewing Sarcoma
Authors: Cornaz-Buros Sandrine , Riggi Nicolo , DeVito Claudio , Sarre Alexandre , Letovanec Igor , Provero Paolo , Stamenkovic Ivan
Published: April 2023

Supplemental Figure Legends. Legends for Supplemental Figures S1-S2.
Data Supplement from Validation and Structural Characterization of the LEDGF/p75–MLL Interface as a New Target for the Treatment of MLL-Dependent Leukemia
Authors: Čermáková Kateřina , Tesina Petr , Demeulemeester Jonas , El Ashkar Sara , Méreau Hélène , Schwaller Juerg , Řezáčová Pavlína , Veverka Vaclav , De Rijck Jan
Published: April 2023

Supplementary Tables S1-S6. Primers used in this study (S1); The statistics for the final water-refined set of NMR structures of IBD-MLL 140-160 complex (S2); The solvent-accessible surface area (BSA) of individual lBD residues buried upon IBD-HIV1-integrase (HIV IN) or IBD-MLL complex formation is expressed as a portion of the residue total solvent accessible area (BSA in %). The BSA was calculated using PDBePISA tool (S3); Effect of LEDGF/p75 mutations on the interaction with MLL as measured by AlphaScreen (S4); Effect of LEDGF/p75 mutations defective for binding to HIV-1 integrase on the interaction with MLL as measured by AlphaScreen (S5); Melting temperatures of the PWWP and IBD domain of wild type LEDGF/p75 or its mutants as determined by DSF (S6).
Supp Table S2 from In Vivo Disruption of an Rb–E2F–Ezh2 Signaling Loop Causes Bladder Cancer
Authors: Santos Mirentxu , Martínez-Fernández Mónica , Dueñas Marta , García-Escudero Ramón , Alfaya Begoña , Villacampa Felipe , Saiz-Ladera Cristina , Costa Clotilde , Oteo Marta , Duarte José , Martínez Victor , Gómez-Rodriguez Ma José , Martín Ma Luisa , Fernández Manoli , Viatour Patrick , Morcillo Miguel A. , Sage Julien , Castellano Daniel , Rodriguez-Peralto Jose L. , de la Rosa Federico , Paramio Jesús M
Published: April 2023

Supp Table S2. Dataset containing the list of upregulated and downregulated genes in mouse bladder tumors.
Supp Table S17 from In Vivo Disruption of an Rb–E2F–Ezh2 Signaling Loop Causes Bladder Cancer
Authors: Santos Mirentxu , Martínez-Fernández Mónica , Dueñas Marta , García-Escudero Ramón , Alfaya Begoña , Villacampa Felipe , Saiz-Ladera Cristina , Costa Clotilde , Oteo Marta , Duarte José , Martínez Victor , Gómez-Rodriguez Ma José , Martín Ma Luisa , Fernández Manoli , Viatour Patrick , Morcillo Miguel A. , Sage Julien , Castellano Daniel , Rodriguez-Peralto Jose L. , de la Rosa Federico , Paramio Jesús M
Published: April 2023

Supp Table S17. Dataset containing the list of upregulated and downregulated genes in human bladder tumors according to progression in recurrence.
Supp Table S16 from In Vivo Disruption of an Rb–E2F–Ezh2 Signaling Loop Causes Bladder Cancer
Authors: Santos Mirentxu , Martínez-Fernández Mónica , Dueñas Marta , García-Escudero Ramón , Alfaya Begoña , Villacampa Felipe , Saiz-Ladera Cristina , Costa Clotilde , Oteo Marta , Duarte José , Martínez Victor , Gómez-Rodriguez Ma José , Martín Ma Luisa , Fernández Manoli , Viatour Patrick , Morcillo Miguel A. , Sage Julien , Castellano Daniel , Rodriguez-Peralto Jose L. , de la Rosa Federico , Paramio Jesús M
Published: April 2023

Supp Table S16. Transcription factor analyzed by Chip Enrichment analysis of the upregulated genes in human recurrent bladder tumors.
Supp Table S12 from In Vivo Disruption of an Rb–E2F–Ezh2 Signaling Loop Causes Bladder Cancer
Authors: Santos Mirentxu , Martínez-Fernández Mónica , Dueñas Marta , García-Escudero Ramón , Alfaya Begoña , Villacampa Felipe , Saiz-Ladera Cristina , Costa Clotilde , Oteo Marta , Duarte José , Martínez Victor , Gómez-Rodriguez Ma José , Martín Ma Luisa , Fernández Manoli , Viatour Patrick , Morcillo Miguel A. , Sage Julien , Castellano Daniel , Rodriguez-Peralto Jose L. , de la Rosa Federico , Paramio Jesús M
Published: April 2023

Supp Table S12. Gene Ontology of Biological processes of the upregulated genes in human recurrent bladder tumors
Data Supplement from Molecular Imaging with Bioluminescence and PET Reveals Viral Oncolysis Kinetics and Tumor Viability
Authors: Kuruppu Darshini , Brownell Anna-Liisa , Shah Khalid , Mahmood Umar , Tanabe Kenneth K.
Published: April 2023

Supplemental Figure 1: Tumor growth imaged with Rluc bioluminescence correlates with volumetric measurements from caliper readings. S1A: 4T1-Rluc tumor growth imaged with Rluc bioluminescence. The area of Rluc expression in the bilateral flank tumors increased over time. S1B: The Rluc signal intensities (expressed as mean net intensity/area +/- SD) increased, corresponding to tumor volume (expressed as the mean +/- SD) obtained with caliper measurements.
Data Supplement from Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor–Modified T Cells in Solid Tumors
Authors: Nishio Nobuhiro , Diaconu Iulia , Liu Hao , Cerullo Vincenzo , Caruana Ignazio , Hoyos Valentina , Bouchier-Hayes Lisa , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

Supplementary Movie 1B. GD2.CAR-T cell
Data Supplement from Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor–Modified T Cells in Solid Tumors
Authors: Nishio Nobuhiro , Diaconu Iulia , Liu Hao , Cerullo Vincenzo , Caruana Ignazio , Hoyos Valentina , Bouchier-Hayes Lisa , Savoldo Barbara , Dotti Gianpietro
Published: April 2023

Supplementary Movie 1D. Ad5ÃŽ?24 and GD2.CAR-T cell
Supplementary Figure S4 from Phosphoinositide Protein Kinase PDPK1 Is a Crucial Cell Signaling Mediator in Multiple Myeloma
Authors: Chinen Yoshiaki , Kuroda Junya , Shimura Yuji , Nagoshi Hisao , Kiyota Miki , Yamamoto-Sugitani Mio , Mizutani Shinsuke , Sakamoto Natsumi , Ri Masaki , Kawata Eri , Kobayashi Tsutomu , Matsumoto Yosuke , Horiike Shigeo , Iida Shinsuke , Taniwaki Masafumi
Published: April 2023

Supplementary Figure S4. A. BX-912 shows no cross-resistance with BTZ. BX-912 exerted its growth inhibitory effect on BTZ-resistant KMS-11/BTZ cells and OPM-2/BTZ cells (red lines) as effectively as on their respective parental cells (blue dotted lines). Cells were treated with the indicated concentrations of either BX-912 or BTZ for 48 hours. The viable cell number of untreated cells was considered to be 1.0. B. The combination of BX-912 and the NF-ÃŽÂºB inhibitor, BAY11-7085, exhibited an additive growth inhibitory effect on BTZ-resistant KMS-11/BTZ cells and OPM-2/BTZ cells. Shaded areas represent the additive effects of the two agents.
Supplemental Figures S1-S8 from Homeoprotein Six2 Promotes Breast Cancer Metastasis via Transcriptional and Epigenetic Control of E-Cadherin Expression
Authors: Wang Chu-An , Drasin David , Pham Catherine , Jedlicka Paul , Zaberezhnyy Vadym , Guney Michelle , Li Howard , Nemenoff Raphael , Costello James C. , Tan Aik-Choon , Ford Heide L.
Published: April 2023

Supplemental Figures S1-S8. SIX2 is overexpressed in breast cancer and correlates with poor prognosis (S1); Six2 KD does not affect proliferation or levels of VEGF-C (S2); Six2 overexpression in 4TO7 cells alters cell morphology but does not increase cell proliferation (S3); Six2 expression in 4TO7 cells increases lung metastasis (S4); Six2 overexpression leads to Zeb2 upregulation in 4TO7 and HMLE cells (S5); SIX2 downregulates miR-8 family members, which when restored to SIX2 overexpressing cells, can reverse the SIX2-induced upregulation of Zeb2 (S6); High levels of SIX2 are found in breast cancer cell lines exhibiting E-cadherin hypermethylation and silencing (S7); SIX2 expression inversely correlates with CDH1 expression in triple negative and non-triple negative breast cancers (S8).
Supplementary Table S6 from Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer
Authors: Mouradov Dmitri , Sloggett Clare , Jorissen Robert N. , Love Christopher G. , Li Shan , Burgess Antony W. , Arango Diego , Strausberg Robert L. , Buchanan Daniel , Wormald Samuel , O'Connor Liam , Wilding Jennifer L. , Bicknell David , Tomlinson Ian P.M. , Bodmer Walter F. , Mariadason John M. , Sieber Oliver M.
Published: April 2023

Levels of mRNA expression for 13 CRC cell lines analyzed using RNA-Seq. Transcript levels are given as reads per kilobase per million mapped (RPKM) values.
Supplemental Movie 1 from AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Authors: Wilson Catherine , Ye Xiaofen , Pham Thinh , Lin Eva , Chan Sara , McNamara Erin , Neve Richard M. , Belmont Lisa , Koeppen Hartmut , Yauch Robert L. , Ashkenazi Avi , Settleman Jeff
Published: April 2023

Timelapse movie of HeLa cells treated with DMSO.
Supplementary Table S3 from Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer
Authors: Mouradov Dmitri , Sloggett Clare , Jorissen Robert N. , Love Christopher G. , Li Shan , Burgess Antony W. , Arango Diego , Strausberg Robert L. , Buchanan Daniel , Wormald Samuel , O'Connor Liam , Wilding Jennifer L. , Bicknell David , Tomlinson Ian P.M. , Bodmer Walter F. , Mariadason John M. , Sieber Oliver M.
Published: April 2023

Sanger sequencing validation for mutations detected by exome-capture sequencing for 12 genes in 43 CRC cell lines. Genes comprised APC, CTNNB1, KRAS, BRAF, NRAS, PIK3CA, PTEN, SMAD2, SMAD3, SMAD4, FBXW7 and TP53. Cell lines included C32, C70, C80, C84, C99, C106, CACO2, COLO201, COLO205, COLO320-DM, COLO678, DLD1, HCA7, HCC2998, HCT8, HCT15, HCT116, HRA19, HT29, HT55, LIM1215, LIM1899, LIM2099, LIM2405, LIM2551, LOVO, LS174T, LS180, LS411, LS513, RKO, RW2982, RW7213, SW48, SW403, SW480, SW620, SW837, SW948, SW1116, SW1222, T84 and VACO4S.
Supplemental Figures S1-S11, Datasets 1-3 from AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Authors: Wilson Catherine , Ye Xiaofen , Pham Thinh , Lin Eva , Chan Sara , McNamara Erin , Neve Richard M. , Belmont Lisa , Koeppen Hartmut , Yauch Robert L. , Ashkenazi Avi , Settleman Jeff
Published: April 2023

Supplemental Figures S1-S11. Figure S1. AXL and GAS6 expression correlates with a mesenchymal signature. Figure S2. AXL staining in TNBC tissues samples. Figure S3. TGF-ÃŽÂ²-induced EMT is reversible, and TKI resistance upon EMT is not due to drug efflux. Figure S4. AXL inhibitor R428 suppresses GAS6-induced pAXL, downstream signaling and invasion capacity. Figure S5: Inhibition of AXL does not re-sensitize erlotinib-resistant cells. Figure S6: AXL over-expression or inhibition does not alter erlotinib sensitivity in the parental HCC827 cell line. Figure S7: Summary of Bliss scores and activity of MP-470, Erlotinib and Docetaxel (DTX) or combination treatment. Figure S8. R428 synergistically interacts with anti-mitotic agents and not with Doxorubicin or Cisplatin to reduce cell viability. Figure S9. AXL inhibition in combination with anti-mitotic agents promotes mitotic death. Figure S10. Suppression of pAKT, pS6 and pCDC2 following AXL inhibition. Figure S11: AXL knock-down increases p21 expression. Table S1. Mesenchymal PC9 cells are cross-resistant to a number of anti-cancer agents.
Supplemental Dataset 3 from AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Authors: Wilson Catherine , Ye Xiaofen , Pham Thinh , Lin Eva , Chan Sara , McNamara Erin , Neve Richard M. , Belmont Lisa , Koeppen Hartmut , Yauch Robert L. , Ashkenazi Avi , Settleman Jeff
Published: April 2023

Supplemental Dataset 3. Tumor cell line profile of docetaxel in combination with R428
Supplementary Table 8 from Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer
Authors: Mouradov Dmitri , Sloggett Clare , Jorissen Robert N. , Love Christopher G. , Li Shan , Burgess Antony W. , Arango Diego , Strausberg Robert L. , Buchanan Daniel , Wormald Samuel , O'Connor Liam , Wilding Jennifer L. , Bicknell David , Tomlinson Ian P.M. , Bodmer Walter F. , Mariadason John M. , Sieber Oliver M.
Published: April 2023

XLSX file - 15KB, Intersecting top 5% of mutated genes based on the proportion of affected samples between CRC cell lines and TCGA-analyzed primary cancers for non-hypermutated and hypermutated MSI-H samples.
Supplemental Text from ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
Authors: Goetz Eva M. , Ghandi Mahmoud , Treacy Daniel J. , Wagle Nikhil , Garraway Levi A.
Published: April 2023

Supplemental Text. Supplemental Materials and Methods, primer sequences, Supplemental Figure Legends, and references.
Supplementary Table 6 from Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer
Authors: Mouradov Dmitri , Sloggett Clare , Jorissen Robert N. , Love Christopher G. , Li Shan , Burgess Antony W. , Arango Diego , Strausberg Robert L. , Buchanan Daniel , Wormald Samuel , O'Connor Liam , Wilding Jennifer L. , Bicknell David , Tomlinson Ian P.M. , Bodmer Walter F. , Mariadason John M. , Sieber Oliver M.
Published: April 2023

XLSX file - 7438KB, Levels of mRNA expression for 13 CRC cell lines analyzed using RNA-Seq. Transcript levels are given as reads per kilobase per million mapped (RPKM) values.
Supplementary Table 4 from Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer
Authors: Mouradov Dmitri , Sloggett Clare , Jorissen Robert N. , Love Christopher G. , Li Shan , Burgess Antony W. , Arango Diego , Strausberg Robert L. , Buchanan Daniel , Wormald Samuel , O'Connor Liam , Wilding Jennifer L. , Bicknell David , Tomlinson Ian P.M. , Bodmer Walter F. , Mariadason John M. , Sieber Oliver M.
Published: April 2023

XLSX file - 12KB, Comparison of POLE mutation spectra between 9 NSHP and 15 non-NSHP CRC cell lines and TCGA-analyzed primary cancers.
Supplementary Table S1 from PAK1 Tyrosine Phosphorylation Is Required to Induce Epithelial–Mesenchymal Transition and Radioresistance in Lung Cancer Cells
Authors: Kim EunGi , Youn HyeSook , Kwon TaeWoo , Son Beomseok , Kang JiHoon , Yang Hee Jung , Seong Ki Moon , Kim Wanyeon , Youn BuHyun
Published: April 2023

Primers for measuring the expression level of EMT-related genes.
Data Supplement from Ubiquitin-like Protein FAT10 Promotes the Invasion and Metastasis of Hepatocellular Carcinoma by Modifying β-Catenin Degradation
Authors: Yuan Rongfa , Wang Kai , Hu Junwen , Yan Chen , Li Ming , Yu Xin , Liu Xiuxia , Lei Jun , Guo Wuhua , Wu Linquan , Hong Kui , Shao Jianghua
Published: April 2023

Supplementary Material,Methods and Figures Legends
Supplementary Figure S1 from Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer
Authors: Mouradov Dmitri , Sloggett Clare , Jorissen Robert N. , Love Christopher G. , Li Shan , Burgess Antony W. , Arango Diego , Strausberg Robert L. , Buchanan Daniel , Wormald Samuel , O'Connor Liam , Wilding Jennifer L. , Bicknell David , Tomlinson Ian P.M. , Bodmer Walter F. , Mariadason John M. , Sieber Oliver M.
Published: April 2023

Correlation between RNA-Seq and gene expression microarray data (Affymetrix U133 Plus2.0 Arrays) for six CRC cell lines analyzed in independent experiments. Genes with detectable expression on both platforms were considered, defined as RNA-Seq RPKM value >1 and microarray intensity > log2(100). r-values, Spearman's rank correlation coefficient.
Supplementary Data and Methods from Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer
Authors: Mouradov Dmitri , Sloggett Clare , Jorissen Robert N. , Love Christopher G. , Li Shan , Burgess Antony W. , Arango Diego , Strausberg Robert L. , Buchanan Daniel , Wormald Samuel , O'Connor Liam , Wilding Jennifer L. , Bicknell David , Tomlinson Ian P.M. , Bodmer Walter F. , Mariadason John M. , Sieber Oliver M.
Published: April 2023

Supplementary Data and Methods
Data Supplement from Ubiquitin-like Protein FAT10 Promotes the Invasion and Metastasis of Hepatocellular Carcinoma by Modifying β-Catenin Degradation
Authors: Yuan Rongfa , Wang Kai , Hu Junwen , Yan Chen , Li Ming , Yu Xin , Liu Xiuxia , Lei Jun , Guo Wuhua , Wu Linquan , Hong Kui , Shao Jianghua
Published: April 2023

Supplementary Figure S1. The FAT10, HOXB9, and β-catenin expression decreased after the transfection of the corresponding shRNA plasmids.
Supplementary Figure Legends from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
Authors: Izumchenko Evgeny , Chang Xiaofei , Michailidi Christina , Kagohara Luciane , Ravi Rajani , Paz Keren , Brait Mariana , Hoque Mohammad O. , Ling Shizhang , Bedi Atul , Sidransky David
Published: April 2023

PDF file - 197KB
Supplementary Figure 4 from The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors
Authors: Izumchenko Evgeny , Chang Xiaofei , Michailidi Christina , Kagohara Luciane , Ravi Rajani , Paz Keren , Brait Mariana , Hoque Mohammad O. , Ling Shizhang , Bedi Atul , Sidransky David
Published: April 2023

PDF file - 137KB, A. Mig6(mRNA)/miR200 ratios plotted on the linear scale. Each bar represents the Mig6(mRNA)/miR200 ratio of an indicated cell line. B. The exposure density of both EGFR and Mig6 blotted on the same membrane were quantified by densitometry and the values of Mig6/EGFR ration for every cell line were plotted on the linear scale.
Supplementary Figure S3 from STAT1 Drives Tumor Progression in Serous Papillary Endometrial Cancer
Authors: Kharma Budiman , Baba Tsukasa , Matsumura Noriomi , Kang Hyun Sook , Hamanishi Junzo , Murakami Ryusuke , McConechy Melissa M. , Leung Samuel , Yamaguchi Ken , Hosoe Yuko , Yoshioka Yumiko , Murphy Susan K. , Mandai Masaki , Hunstman David G. , Konishi Ikuo
Published: April 2023

Supplementary Figure S3. Activity of STAT1 pathway genes in endometrial cancer cells.
Supplemental Figure Legends from Long-Chain Fatty Acid Analogues Suppress Breast Tumorigenesis and Progression
Authors: Gluschnaider Udi , Hertz Rachel , Ohayon Sarit , Smeir Elia , Smets Martha , Pikarsky Eli , Bar-Tana Jacob
Published: April 2023

Supplemental Figure Legends. Legends for Supplemental Figures S1-S3.
Supplementary Methods, Figure Legends from Rapamycin Rescues ABT-737 Efficacy in Small Cell Lung Cancer
Authors: Gardner Eric E. , Connis Nick , Poirier John T. , Cope Leslie , Dobromilskaya Irina , Gallia Gary L. , Rudin Charles M. , Hann Christine L.
Published: April 2023

PDF file - 84KB
Supplementary Figures S1-S5 from A Small-Molecule Modulator of the Tumor-Suppressor miR34a Inhibits the Growth of Hepatocellular Carcinoma
Authors: Xiao Zhangang , Li Chi Han , Chan Stephen L. , Xu Feiyue , Feng Lu , Wang Yan , Jiang Jian-Dong , Sung Joseph J.Y. , Cheng Christopher H.K. , Chen Yangchao
Published: April 2023

Supplementary Figures S1-S5. The established miR-34a reporter was responsive to the endogeneous miR-34a level (S1); Rubone activated the expression of miR-34a (S2); Rubone inhibited Huh7 xenografted tumor growth (S3); Rubone activated pri-miR-34a expressions and inhibited angiogenesis in HepG2 xenografts (S4); Knockdown of p53 reversed pri-miR-34a expression and cell growth inhibition induced by Rubone in HepG2 and Bel-7404 cells (S5).
Supplementary Figure Legends from A Small-Molecule Modulator of the Tumor-Suppressor miR34a Inhibits the Growth of Hepatocellular Carcinoma
Authors: Xiao Zhangang , Li Chi Han , Chan Stephen L. , Xu Feiyue , Feng Lu , Wang Yan , Jiang Jian-Dong , Sung Joseph J.Y. , Cheng Christopher H.K. , Chen Yangchao
Published: April 2023

Supplementary Figure Legends. Legend for Supplementary Figures S1-S5.
Supplemental Table S3 from H3K9 Histone Methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 Pathway to Suppress Lung Cancer Metastasis
Authors: Wu Pei-Chun , Lu Jeng-Wei , Yang Jer-Yen , Lin I-Hsuan , Ou Da-Liang , Lin Yu-Hsiang , Chou Kuan-Hsien , Huang Wen-Feng , Wang Wan-Ping , Huang Yih-Leh , Hsu Chiun , Lin Liang-In , Lin Yueh-Min , Shen C.-K. James , Tzeng Tsai-Yu
Published: April 2023

KMT1E DNA binding sequences identified by ChIP-Seq.
Supplemental Materials and Methods from H3K9 Histone Methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 Pathway to Suppress Lung Cancer Metastasis
Authors: Wu Pei-Chun , Lu Jeng-Wei , Yang Jer-Yen , Lin I-Hsuan , Ou Da-Liang , Lin Yu-Hsiang , Chou Kuan-Hsien , Huang Wen-Feng , Wang Wan-Ping , Huang Yih-Leh , Hsu Chiun , Lin Liang-In , Lin Yueh-Min , Shen C.-K. James , Tzeng Tsai-Yu
Published: April 2023

revised supporting materials and methods
Supplementary Figures S1-S15 from Targeting the c-Met/FZD8 Signaling Axis Eliminates Patient-Derived Cancer Stem–like Cells in Head and Neck Squamous Carcinomas
Authors: Sun Shuyang , Liu Suling , Duan Sheng Zhong , Zhang Lei , Zhou Henghua , Hu Yongjie , Zhou Xianghui , Shi Chaoji , Zhou Rong , Zhang Zhiyuan
Published: April 2023

Supplementary Figures S1-S15. Identification and enrichment of CSCs directly from clinical SCCHN samples ; qRT-PCR measurement of the c-Met mRNA level and western blot measurement of c-Met protein in HN-CSC#1 spheres, HN-CSC#2 spheres, and HN-CSC#3 spheres infected with lentiviral nonspecific shRNA (scramble) or c-Met-specific shRNAs ; Knockdown of c-Met inhibited the properties of HN-CSCs ; Dose-dependent effect of conventional chemotherapeutic agents (cisplatin, 5-Fu, and docetaxel) on the viability of tumor cells derived from patient HN-0-22, HN-0-29, or HN-0-46 ; Treatment with c-Met inhibitor PF-2341066 inhibited the formation of HN-CSC#2 spheres and HN-CSC#3 spheres in a dose-dependent manner ; Treatment with c-Met inhibitor SU11274 inhibited the formation of HN-CSC#1 spheres and HN-CSC#2 spheres in a dose-dependent manner ; The combination of c-Met inhibition and docetaxel treatment eliminates CSCs in patient-derived tumor xenografts ; Pharmacologic inhibition of c-Met enhances the therapeutic efficacy of conventional anti-cancer agent 5-Fu ; Western blot analysis shows that no anaplastic lymphoma kinase (ALK) expression was detected in seven SCCHN PDXs including HN-0-22, HN-0-29, and HN-0-46-derived xenografts ; Histologic confirmation of metastasis by H&E staining ; RT2 Profiler PCR Array and further qPCR validation ; Downregulation of FZD8-mediated Wnt/β-catenin signaling is a crucial step for the elimination of HN-CSCs caused by c-Met inhibition ; Quantification of the normalized photon flux, measured at weekly intervals following cells inoculation ; Western blot analyses ; C-Met functionally regulates FZD8 through an ERK/c-Fos cascade in HN-CSCs .
Supplemental Figure S7 from H3K9 Histone Methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 Pathway to Suppress Lung Cancer Metastasis
Authors: Wu Pei-Chun , Lu Jeng-Wei , Yang Jer-Yen , Lin I-Hsuan , Ou Da-Liang , Lin Yu-Hsiang , Chou Kuan-Hsien , Huang Wen-Feng , Wang Wan-Ping , Huang Yih-Leh , Hsu Chiun , Lin Liang-In , Lin Yueh-Min , Shen C.-K. James , Tzeng Tsai-Yu
Published: April 2023

KMT1E modulates ANXA2 expression to suppress cancer cell invasion in lung cancer cells.
Supplemental Figure S1 from H3K9 Histone Methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 Pathway to Suppress Lung Cancer Metastasis
Authors: Wu Pei-Chun , Lu Jeng-Wei , Yang Jer-Yen , Lin I-Hsuan , Ou Da-Liang , Lin Yu-Hsiang , Chou Kuan-Hsien , Huang Wen-Feng , Wang Wan-Ping , Huang Yih-Leh , Hsu Chiun , Lin Liang-In , Lin Yueh-Min , Shen C.-K. James , Tzeng Tsai-Yu
Published: April 2023

Cell viability effects of KMT1E in lung cancer.
Supplementary Figures S1-S5 from CDC42 Inhibition Suppresses Progression of Incipient Intestinal Tumors
Authors: Sakamori Ryotaro , Yu Shiyan , Zhang Xiao , Hoffman Andrew , Sun Jiaxin , Das Soumyashree , Vedula Pavan , Li Guangxun , Fu Jiang , Walker Francesca , Yang Chung S. , Yi Zheng , Hsu Wei , Yu Da-Hai , Shen Lanlan , Rodriguez Alexis J. , Taketo Makoto M. , Bonder Edward M. , Verzi Michael P. , Gao Nan
Published: April 2023

Epithelial deletion of Cdc42 abrogates APCMin/+ tumorigenesis (S1); Improved body weight in Catnb(ex3)/+;Cdc42fl/+;Vil-Cre mice (S2); Epithelial Cdc42 deletion alleviated formation of crypt-like foci (S3); Cdc42 deletion reduced Paneth-like cells in microadenoma foci (S4); CASIN treatment arrested LIM1863 tumor organoids (S5).
Supplementary Figure Legend from CDC42 Inhibition Suppresses Progression of Incipient Intestinal Tumors
Authors: Sakamori Ryotaro , Yu Shiyan , Zhang Xiao , Hoffman Andrew , Sun Jiaxin , Das Soumyashree , Vedula Pavan , Li Guangxun , Fu Jiang , Walker Francesca , Yang Chung S. , Yi Zheng , Hsu Wei , Yu Da-Hai , Shen Lanlan , Rodriguez Alexis J. , Taketo Makoto M. , Bonder Edward M. , Verzi Michael P. , Gao Nan
Published: April 2023

Legend for Supplementary Figures S1-S5.
Data Supplement from Novel Drug Candidates for the Treatment of Metastatic Colorectal Cancer through Global Inverse Gene-Expression Profiling
Authors: van Noort Vera , Schölch Sebastian , Iskar Murat , Zeller Georg , Ostertag Kristina , Schweitzer Christine , Werner Kristin , Weitz Jürgen , Koch Moritz , Bork Peer
Published: April 2023

Supplementary Figure S1. Benchmarking anti-correlated drug-disease relations with known drug indications. Supplementary Figure S2. Genes in the metastatic gene profile. Supplementary Figure S3. Fraction of apoptotic cells after treatment with candidate drugs. Supplementary Figure S4. Four circulating tumor cells.
Supplementary Table S2 from Harnessing the Fcμ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia
Authors: Vire Bérengère , Skarzynski Martin , Thomas Joshua D. , Nelson Christopher G. , David Alexandre , Aue Georg , Burke Terrence R. , Rader Christoph , Wiestner Adrian
Published: April 2023

This table describes relapsed or refractory patients characteristics.
Supplementary Methods from Harnessing the Fcμ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia
Authors: Vire Bérengère , Skarzynski Martin , Thomas Joshua D. , Nelson Christopher G. , David Alexandre , Aue Georg , Burke Terrence R. , Rader Christoph , Wiestner Adrian
Published: April 2023

This file describes the supplementary materials and methods.
Supplementary Figure Legends from Harnessing the Fcμ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia
Authors: Vire Bérengère , Skarzynski Martin , Thomas Joshua D. , Nelson Christopher G. , David Alexandre , Aue Georg , Burke Terrence R. , Rader Christoph , Wiestner Adrian
Published: April 2023

This file contains figure legends for all supplementary figures.
Supplementary Figure 3 from Harnessing the Fcμ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia
Authors: Vire Bérengère , Skarzynski Martin , Thomas Joshua D. , Nelson Christopher G. , David Alexandre , Aue Georg , Burke Terrence R. , Rader Christoph , Wiestner Adrian
Published: April 2023

Supplementary Figure 3 shows that unconjugated Fcµ-Sec has no anti-tumor activity.
Supplementary Figure 2 from Harnessing the Fcμ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia
Authors: Vire Bérengère , Skarzynski Martin , Thomas Joshua D. , Nelson Christopher G. , David Alexandre , Aue Georg , Burke Terrence R. , Rader Christoph , Wiestner Adrian
Published: April 2023

Supplementary Figure 2 shows the circulatory half-life of Fcµ-Sec in NSG mice.
Supplementary Figure 1 from Harnessing the Fcμ Receptor for Potent and Selective Cytotoxic Therapy of Chronic Lymphocytic Leukemia
Authors: Vire Bérengère , Skarzynski Martin , Thomas Joshua D. , Nelson Christopher G. , David Alexandre , Aue Georg , Burke Terrence R. , Rader Christoph , Wiestner Adrian
Published: April 2023

Supplementary Figure 1 shows Western Blot analysis of purified Fcµ-Sec constructs.
Supplemental Figure S3 from CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy
Authors: Soto-Pantoja David R. , Terabe Masaki , Ghosh Arunima , Ridnour Lisa A. , DeGraff William G. , Wink David A. , Berzofsky Jay A. , Roberts David D.
Published: April 2023

Supplemental Figure S3. Efficiency of CD47 protein knockdown by CD47 morpholino.
Supplemental Models from Mathematical Modeling of Tumor Growth and Metastatic Spreading: Validation in Tumor-Bearing Mice
Authors: Hartung Niklas , Mollard Séverine , Barbolosi Dominique , Benabdallah Assia , Chapuisat Guillemette , Henry Gerard , Giacometti Sarah , Iliadis Athanassios , Ciccolini Joseph , Faivre Christian , Hubert Florence
Published: April 2023

This file provides some details on the mathematical models and their properties.
Supplementary Table 1 from Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs
Authors: Pennacchietti Selma , Cazzanti Manuela , Bertotti Andrea , Rideout William M. , Han May , Gyuris Jeno , Perera Timothy , Comoglio Paolo M. , Trusolino Livio , Michieli Paolo
Published: April 2023

Supplementary Tab. 1. HGF protects MET-addicted tumor cells against MET-targeted agents.
Supplementary Figure 5 from Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs
Authors: Pennacchietti Selma , Cazzanti Manuela , Bertotti Andrea , Rideout William M. , Han May , Gyuris Jeno , Perera Timothy , Comoglio Paolo M. , Trusolino Livio , Michieli Paolo
Published: April 2023

Supplementary Fig. 5. Human HGF knock-in SCID mice display a physiological HGF expression pattern.
Data Supplement from IL15RA Drives Antagonistic Mechanisms of Cancer Development and Immune Control in Lymphocyte-Enriched Triple-Negative Breast Cancers
Authors: Marra Pierfrancesco , Mathew Sumi , Grigoriadis Anita , Wu Yin , Kyle-Cezar Fernanda , Watkins Johnathan , Rashid Mamunur , De Rinaldis Emanuele , Hessey Sonya , Gazinska Patrycja , Hayday Adrian , Tutt Andrew
Published: April 2023

Legend for Supplementary Figure S1
Supplementary Figure 4 from Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs
Authors: Pennacchietti Selma , Cazzanti Manuela , Bertotti Andrea , Rideout William M. , Han May , Gyuris Jeno , Perera Timothy , Comoglio Paolo M. , Trusolino Livio , Michieli Paolo
Published: April 2023

Supplementary Fig. 4. Low concentrations of HGF are sufficient to fully antagonize DN30 Fab-induced EBC-1 lung carcinoma cell growth inhibition.
Supplementary Figure 3 from Microenvironment-Derived HGF Overcomes Genetically Determined Sensitivity to Anti-MET Drugs
Authors: Pennacchietti Selma , Cazzanti Manuela , Bertotti Andrea , Rideout William M. , Han May , Gyuris Jeno , Perera Timothy , Comoglio Paolo M. , Trusolino Livio , Michieli Paolo
Published: April 2023

Supplementary Fig. 3. HGF restores physiological, GAB-1-mediated MET signaling in DN30 Fab-treated MET-addicted cells.
Supplementary Figure 1 from Hippo Coactivator YAP1 Upregulates SOX9 and Endows Esophageal Cancer Cells with Stem-like Properties
Authors: Song Shumei , Ajani Jaffer A. , Honjo Soichiro , Maru Dipen M. , Chen Qiongrong , Scott Ailing W. , Heallen Todd R. , Xiao Lianchun , Hofstetter Wayne L. , Weston Brian , Lee Jeffrey H. , Wadhwa Roopma , Sudo Kazuki , Stroehlein John R. , Martin James F. , Hung Mien-Chie , Johnson Randy L.
Published: April 2023

PDF file - 1574K, YAP1 and SOX9 expression in EC cell lines.
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Authors: Watson Ian R. , Li Liren , Cabeceiras Peter K. , Mahdavi Mozhdeh , Gutschner Tony , Genovese Giannicola , Wang Guocan , Fang Zhuangna , Tepper James M. , Stemke-Hale Katherine , Tsai Kenneth Y. , Davies Michael A. , Mills Gordon B. , Chin Lynda
Published: April 2023

Supplementary Table 1. (Top) IC50 (nM), fold changes (FC) and (Bottom) % viability at 10uM drug treatment compared to DMSO control for BRAF mutant cell lines, A375, MALME-3M, 451Lu and IGR1 (expresses RAC1 P29S) are shown.
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Authors: Watson Ian R. , Li Liren , Cabeceiras Peter K. , Mahdavi Mozhdeh , Gutschner Tony , Genovese Giannicola , Wang Guocan , Fang Zhuangna , Tepper James M. , Stemke-Hale Katherine , Tsai Kenneth Y. , Davies Michael A. , Mills Gordon B. , Chin Lynda
Published: April 2023

Supplementary Table 3. IC50s (nM) and fold changes (FC) comparing IC50s of RAC1 wild-type and P29S mutant to GFP are shown for indicated drug, cell lines and expression plasmid.
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Authors: Watson Ian R. , Li Liren , Cabeceiras Peter K. , Mahdavi Mozhdeh , Gutschner Tony , Genovese Giannicola , Wang Guocan , Fang Zhuangna , Tepper James M. , Stemke-Hale Katherine , Tsai Kenneth Y. , Davies Michael A. , Mills Gordon B. , Chin Lynda
Published: April 2023

Supplementary Table 4. STR profiles for cell lines used in this study.
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Authors: Watson Ian R. , Li Liren , Cabeceiras Peter K. , Mahdavi Mozhdeh , Gutschner Tony , Genovese Giannicola , Wang Guocan , Fang Zhuangna , Tepper James M. , Stemke-Hale Katherine , Tsai Kenneth Y. , Davies Michael A. , Mills Gordon B. , Chin Lynda
Published: April 2023

Supplementary Figure 1: Identification of RAC1 P29S mutant melanoma cell lines.
Data Supplement from The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF
Authors: Watson Ian R. , Li Liren , Cabeceiras Peter K. , Mahdavi Mozhdeh , Gutschner Tony , Genovese Giannicola , Wang Guocan , Fang Zhuangna , Tepper James M. , Stemke-Hale Katherine , Tsai Kenneth Y. , Davies Michael A. , Mills Gordon B. , Chin Lynda
Published: April 2023

Supplementary Figure 3: Overexpression of RAC1 P29S increases cell viability of 451Lu cells to RAF and MEK inhibitor treatment.
Data Supplement from Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy
Authors: Arthur Laura M. , Turnbull Arran K. , Webber Victoria L. , Larionov Alexey A. , Renshaw Lorna , Kay Charlene , Thomas Jeremy S. , Dixon J. Michael , Sims Andrew H.
Published: April 2023

Microsoft Excel workbook containing the following gene lists and information; A) 500 most variable genes from Figure 1D, B) differentially expressed genes between ILC and IDC at baseline and 3 months of treatment using Rank Products with a cut-off of 0.05 PFP figure 2, C) differentially expressed genes after 3 months of letrozole in ILC and IDCILC tumors using pairwise Rank Products with a cut-off of 0.05 PFP (percent false positive) from figure 3, D) genes from Sikora et al. 2014 [5] that were represented in the combined Affymetrix/Illumina dataset, E) Additional sample information including the NCBI GEO Accession numbers of the Affymetrix data.
Supplementary Figure 5 from Development of Novel ADCs: Conjugation of Tubulysin Analogues to Trastuzumab Monitored by Dual Radiolabeling
Authors: Cohen Ruth , Vugts Danielle J. , Visser Gerard W.M. , Stigter-van Walsum Marijke , Bolijn Marije , Spiga Marco , Lazzari Paolo , Shankar Sreejith , Sani Monica , Zanda Matteo , van Dongen Guus A.M.S.
Published: April 2023

In vivo efficacy of TUB-OMOM-trastuzumab JIMT-tumor bearing mice. The effect after a single i.p. injection of NaCl (control, red line), trastuzumab (15 mg/kg, green line),15 mg/kg TUB-OMOM-trastuzumab (blue line), 30 mg/kg TUB-OMOM-trastuzumab (purple line) 60 mg/kg TUB-OMOM-trastuzumab (orange line) or trastuzumab emtansine (T-DM1; 15 mg/kg, black line). Error bars are not shown, due to large differences in tumor growth in time.
Supplementary Figure 1 from Promoting Thiol Expression Increases the Durability of Antitumor T-cell Functions
Authors: Kesarwani Pravin , Al-Khami Amir A. , Scurti Gina , Thyagarajan Krishnamurthy , Kaur Navtej , Husain Shahid , Fang Quan , Naga Osama S. , Simms Patricia , Beeson Gyda , Voelkel-Johnson Christina , Garrett-Mayer Elizabeth , Beeson Craig C. , Nishimura Michael I. , Mehrotra Shikhar
Published: April 2023

Supplementary Figure 1. Differential apoptosis in CD62Llo and CD62Lhi CD8+ T cells
Supplemental Legends from Zfx Facilitates Tumorigenesis Caused by Activation of the Hedgehog Pathway
Authors: Palmer Colin J. , Galan-Caridad Jose M. , Weisberg Stuart P. , Lei Liang , Esquilin Jose M. , Croft Gist F. , Wainwright Brandon , Canoll Peter , Owens David M. , Reizis Boris
Published: April 2023

Supplemental figure legends
Supplementary Figure Legends, Table 1 from Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
Authors: Ho Ping-Chih , Meeth Katrina M. , Tsui Yao-Chen , Srivastava Bhaskar , Bosenberg Marcus W. , Kaech Susan M.
Published: April 2023

PDF file - 90KB, Supplementary Table 1. Quantitative PCR primer sequences.
Supplementary Figure 5 from Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ
Authors: Ho Ping-Chih , Meeth Katrina M. , Tsui Yao-Chen , Srivastava Bhaskar , Bosenberg Marcus W. , Kaech Susan M.
Published: April 2023

PDF file - 511KB, Supplementary Figure 5. PLX4720 treatment inhibits melanoma growth is independent of CD70.
Data Supplement from TALEN-Mediated Somatic Mutagenesis in Murine Models of Cancer
Authors: Zhang Shuyuan , Li Lin , Kendrick Sara L. , Gerard Robert D. , Zhu Hao
Published: April 2023

Supplementary Figure 6. Expression screening of adenoviral plaques for Ad-Apc-TAL
Supplementary Methods and References from Suppression of Deacetylase SIRT1 Mediates Tumor-Suppressive NOTCH Response and Offers a Novel Treatment Option in Metastatic Ewing Sarcoma
Authors: Ban Jozef , Aryee Dave N.T. , Fourtouna Argyro , van der Ent Wietske , Kauer Max , Niedan Stephan , Machado Isidro , Rodriguez-Galindo Carlos , Tirado Oscar M. , Schwentner Raphaela , Picci Piero , Flanagan Adrienne M. , Berg Verena , Strauss Sandra J. , Scotlandi Katia , Lawlor Elizabeth R. , Snaar-Jagalska Ewa , Llombart-Bosch Antonio , Kovar Heinrich
Published: April 2023

Supplementary Methods and References. Description of additional methods and procedures used in the study. Also includes Supplementary References.
Supplementary Figure 4 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Authors: Deng Jiusheng , Yuan Shala , Pennati Andrea , Murphy Jordan , Wu Jian Hui , Lawson David , Galipeau Jacques
Published: April 2023

PDF file - 27K, Murine GIFT4-B cells enhance T-cell IFN-γ production.
Supplementary Figure 2 from Engineered Fusokine GIFT4 Licenses the Ability of B Cells to Trigger a Tumoricidal T-cell Response
Authors: Deng Jiusheng , Yuan Shala , Pennati Andrea , Murphy Jordan , Wu Jian Hui , Lawson David , Galipeau Jacques
Published: April 2023

PDF file - 79K, Secretome of murine GIFT4-B cells.
Supplementary Data from Molecular Characterization of Chronic-type Adult T-cell Leukemia/Lymphoma
Authors: Yoshida Noriaki , Karube Kennosuke , Utsunomiya Atae , Tsukasaki Kunihiro , Imaizumi Yoshitaka , Taira Naoya , Uike Naokuni , Umino Akira , Arita Kotaro , Suguro Miyuki , Tsuzuki Shinobu , Kinoshita Tomohiro , Ohshima Koichi , Seto Masao
Published: April 2023

Supplementary Data. 1. Supplementary Methods 2. Supplementary Data Supplementary Table 1, Patient information at sampling. Supplementary Figure 1, A: Genomic alterations of both tumor and normal samples in Cases A-16, A-20, and A-35. B: Analysis of TCR-γ gene rearrangement in a case. Supplementary Figure 2, Re-expression of INK4a or ARF into ATL cell lines. Supplementary Table 2, Status of CD58 and B2M in ATL samples. Supplementary Table 3, Genetic alterations related to acute transformation of chronic type ATL. 3. References
Supplementary Figure S4 from Myostatin Gene Inactivation Prevents Skeletal Muscle Wasting in Cancer
Authors: Gallot Yann S. , Durieux Anne-Cécile , Castells Josiane , Desgeorges Marine M. , Vernus Barbara , Plantureux Léa , Rémond Didier , Jahnke Vanessa E. , Lefai Etienne , Dardevet Dominique , Nemoz Georges , Schaeffer Laurent , Bonnieu Anne , Freyssenet Damien G.
Published: April 2023

Effect of human recombinant Mstn (hrMstn) on the proliferation of Lewis lung carcinoma (LLC) cells - Bcl-2 protein content in the tumor tissue.
Supplementary Figure Legend from Myostatin Gene Inactivation Prevents Skeletal Muscle Wasting in Cancer
Authors: Gallot Yann S. , Durieux Anne-Cécile , Castells Josiane , Desgeorges Marine M. , Vernus Barbara , Plantureux Léa , Rémond Didier , Jahnke Vanessa E. , Lefai Etienne , Dardevet Dominique , Nemoz Georges , Schaeffer Laurent , Bonnieu Anne , Freyssenet Damien G.
Published: April 2023

Legend for Supplementary Figures S1-S6.
Supplementary Figure S1 from Complex Formation and Function of Estrogen Receptor α in Transcription Requires RIP140
Authors: Rosell Meritxell , Nevedomskaya Ekaterina , Stelloo Suzan , Nautiyal Jaya , Poliandri Ariel , Steel Jennifer H. , Wessels Lodewyk F.A. , Carroll Jason S. , Parker Malcolm G. , Zwart Wilbert
Published: April 2023

Supplementary Figure S1. RIP140 and ERα protein levels in response to E2 treatment.
Supplymentary Table 1 and Figure Legends from LASP1 Is a HIF1α Target Gene Critical for Metastasis of Pancreatic Cancer
Authors: Zhao Tiansuo , Ren He , Li Jing , Chen Jing , Zhang Huan , Xin Wen , Sun Yan , Sun Lei , Yang Yongwei , Sun Junwei , Wang Xiuchao , Gao Song , Huang Chongbiao , Zhang Huafeng , Yang Shengyu , Hao Jihui
Published: April 2023

Supplementary Table 1. Antibodies and primers.